Congenital anomalies of the kidney and urinary tract (CAKUT) are a major cause of pediatric kidney failure. We performed a genome-wide analysis of copy number variants (CNVs) in 2,824 cases and 21,498 controls. Affected individuals carried a significant burden of rare exonic (that is, affecting coding regions) CNVs and were enriched for known genomic disorders (GD). loci (1q21, 4p16.1-p16.3, 16p11.2,  16p13.11, 17q12 and 22q11.2) accounted for 65% of patients with GD-CNVs. Deletions at 17q12, 4p16.1-p16.3 and 22q11 .2 were specific for KA; the 16p11.2 locus showed extensive pleiotropy. Using a multidisciplinary approach, we identified TBX6 as a driver for the CAKUT subphenotypes in the 16p11.2 microdeletion syndrome.
spectrum of CAKUT. Conversely, differences in the prevalence and severity of structural malformations point toward a distinct molecular basis and genetic architecture 22, 23 . To date, there are more than 50 single-gene disorders known to underlie isolated and nonisolated (that is, syndromic) CAKUT 5, 24, 25 . Furthermore, a substantial number of CAKUT patients carry copy number variants (CNV) that were previously associated with a syndrome diagnosis or are large and extremely rare in the general population [26] [27] [28] . Nevertheless, a molecular diagnosis can be established in less than 20% of affected individuals [15] [16] [17] [29] [30] [31] [32] , thus emphasizing that large studies across the entire phenotypic spectrum of CAKUT are indispensable to identify genes and allelic variants that either are specific to subcategories of disease or have pleiotropic effects across the entire genitourinary tract, and to discover novel cellular pathways that are implicated in kidney and urinary development.
Here, we show the presence of a distinct genetic architecture as well as pleiotropic mutations for the different subphenotypes of CAKUT. Our CNV analysis of nearly 3,000 cases across the phenotypic spectrum of CAKUT sheds light on the genomic architecture of disease and implicates TBX6 as a main driver for the various CAKUT phenotypes in the 16p11.2 microdeletion syndrome.
Further annotation identified 54 large, rare, exonic CNVs in an additional 47 CAKUT cases (1.7%) that fulfilled ACMG criteria 35, 36 as likely pathogenic imbalances (Methods and Supplementary Table 11 ). Among these, the CNVs classified as pathogenic were an atypical deletion at the 16p11.2 locus (described below), a 300-kb deletion involving PAX2, a 100-kb duplication containing TBX18, a 571-kb deletion spanning PBX1 and a 6.8-Mb duplication including BMP4 ( Supplementary Fig. 8a-d ). We also identified overlapping duplications at the 15p11.2 locus in five cases with ureteric defects (VUR, OU) and PUV, as well as two KA cases with deletions proximal to the 16p11.2 microdeletion syndrome. In line with the burden test results, the distribution of deletions and duplications at known and novel GD-CNV loci (Fig. 1c,d ) was significantly different among CAKUT categories (6 × 2 Fisher's exact test P = 8.93 × 10 −5 ). In particular, subjects with KA and OU were enriched for deletion syndromes, contrary to PUV and DCS, which showed an excess of duplications at the same genomic loci.
When we examined associations with disease severity, cases with a known GD-CNV were more likely to have multiple sites of the urinary tract affected (OR 1.60, 95% CI 1.05-2.42; P = 0.02) and more frequently harbored extrarenal malformations (OR 4.79, 95% CI 3.21-7.17; P = 6.00 × 10 -15 ) than did cases without a known GD-CNV. However, in agreement with the burden tests conducted above, analysis of simplex isolated cases still showed a greater burden than that of controls (OR 3.12, 95% CI 2.06-4.61; P = 1.86 x 10 −7 ), thus strongly implicating the importance of GD-CNVs in milder forms of CAKUT. To test more complex genetic models for modes of disease determination, we examined cases and controls for second-site CNVs. Among the 159 cases with GD-CNVs (112 known, 47 new/likely pathogenic, altogether called 'diagnostic CNVs' (DCNVs)), 11 (6.9%) carried more than one DCNV ( Supplementary Table 12 ). In cases, the presence of zero, one or more than one DCNV increased the likelihood of extrarenal malformations (chi-square test for 3 × 2 table: P = 6.94 x 10 −7 ; Supplementary Fig. 9 ).
KA, OU and VUR show distinct genomic characteristics.
A comparison of CNV landscapes between the largest CAKUT subcategories revealed both commonalities and differences between KA, OU and VUR ( Table 2) . We found significant CNV enrichment for all three phenotypes, which was most uniformly shown by a larger different ancestries, as estimated by principal component analysis ( Supplementary Fig. 2 ).
This analysis revealed a marked enrichment for large, rare CNVs in CAKUT compared with controls (P = 1.04 × 10 −24 ; Fig. 1a ), which was consistent across virtually all metrics examined, including the number of individuals with large, rare CNVs, the median size and total CNV span per genome, and the fraction of GD-CNVs, thus indicating an important role for gene-disrupting CNVs across the entire CAKUT spectrum (Table 1 and Supplementary Table 3 ). This signal was driven by cases with and without extrarenal manifestations, because the burden difference was still highly significant in analysis of cases without extrarenal defects separately (P = 3.21 × 10 −8 ; Fig. 1a,b and Supplementary Figs. 3 and 4). Even when only simplex isolated CAKUT cases (that is, cases without extrarenal manifestation and with no additional CAKUT phenotypes other than the primary one) were considered, there was still an excess burden of large, rare CNVs compared with controls (P = 1.15 × 10 −8 ; Supplementary Fig. 5 ). Comparison of burden metrics for cases and controls indicated a population attributable risk of 4.1% for large, rare CNVs ≥ 500 kb in CAKUT (odds ratio (OR) 1.64, 95% confidence interval (CI) 1.44-1.87; P = 3.23 × 10 −13 ). This excess burden is predominantly attributable to exonic deletions, most prominently in the KA cases (Supplementary Tables 4 and 5) . Interestingly, we observed an enrichment for rare duplications compared with deletions in VUR and PUV cases compared with controls (P = 3.33 × 10 −2 and P = 8.67 × 10 −4 , respectively; Supplementary Fig. 6 ). Secondary analysis also showed enrichment of the number of genes per individual genome that were affected by rare CNVs for nearly all CAKUT subcategories (Supplementary Table 6 and Supplementary Fig. 7 ).
Genomic disorders inform about the genetic architecture of CAKUT. We cross-annotated all rare CNVs with a curated list of known GDs 33, 34 (Supplementary Table 7 ) and identified 45 distinct known GDs in 112 (4.0%) independent cases ( Fig. 1c and Supplementary Table 8 ). Five cases carried more than one known GD-CNV, resulting in a total number of 117 known GD-CNVs in our cohort ( Supplementary Table 9 ); in comparison, known GD-CNVs were found in only 134/21,498 (0.6%) population controls (OR 6.58, 95% CI 5.05-8.55; P = 7.53 × 10 −41 ; Supplementary Table 10 ). indicating that novel syndromes account for the molecular basis of this disorder ( Table 2 , Fig. 1d and Supplementary Figs. 3 and 10 ). Finally, OU cases fell in an intermediate category, with CNVs that were not statistically larger than those of controls, yet the excess CNV burden (P = 0.01; Supplementary Fig. 3 ) was reflected by a greater proportion of individuals with large imbalances that were also more likely to be classified as pathogenic GD-CNVs (11 cases with GD-CNVs, OR 3.50, 95% CI 1.70-6.52; P = 5.96 × 10 −4 ; Table 3 and Supplementary Fig. 3 ). These data suggest a distinct genomic architecture among CAKUT subcategories, with enrichment of GD-CNVs in KA and enrichment for novel, large-or intermediatesized imbalances in VUR and OU, respectively.
Six GD loci account for 65% of CAKUT cases with known GD-CNVs. We conducted a literature search, including a survey of proportion of cases carrying exonic CNVs ≥ 100 kb than controls. KA cases had the highest CNV burden (P = 9.01 x 10 −25 ; Fig. 1b ), as evidenced by median CNV size and total span, as well as the proportion of individuals with large imbalances that could be classified as pathogenic GD-CNVs (80 cases with GD-CNVs, OR 12.65, 95% CI 9.40-16.94; P = 8.53 × 10 −50 ; Table 2 and Fig. 1c ). After removal of individuals with a known GD-CNV, the strength of the excess CNV burden in KA was still detectable but markedly attenuated (P = 1.27 × 10 −3 ), in agreement with the major role for GD-CNVs in the pathogenesis of KA ( Supplementary Fig. 10 ). In contrast, VUR cases were also affected by a high CNV burden (P = 7.56 × 10 −7 ), but these CNVs predominantly involved duplications and were less likely to be classified as GD-CNVs (seven cases with GD-CNVs, OR 1.71; 95% CI 0.67-3.64; P = 0.20; Fig. 1c ). The large rare CNVs in VUR were mostly classified as likely pathogenic, thus potentially lesions result in specific CAKUT subphenotypes, whereas other genetic lesions, such as the 16p11.2 microdeletion syndrome, have high pleiotropic effects across the genitourinary tract. These loci provide a list of regions that are likely to encompass critical regulators of kidney and urinary tract development in humans, offering a unique opportunity for gene discovery.
Exome sequencing indicates haploinsufficiency underlying CNV deletions.
To test the mechanism through which pathogenic CNVs confer risk for CAKUT, we conducted whole-exome sequencing (WES) in 23 patients with pathogenic microdeletions at 14 independent loci ( Supplementary Table 13 ). On the basis of recessive lossof-function (LOF) inheritance, WES would uncover a hemizygous LOF mutation on the nondeleted allele (unmasking effect). WES was performed as previously described 18, 23, 54 . We retrieved all identified candidate hemizygous LOF variants located within the casespecific deletion loci. Overall, we identified only one LOF variant in EFCAB12 (p.Q437*; observed once in heterozygosity in the Exome Aggregation Consortium database (ExAC) database 55, 56 ) in a patient affected by unilateral KA and multiple extrarenal manifestations, including neurodevelopmental delay, epilepsy, corpus callosum agenesis, left radial bone agenesis and a patent ductus arteriosus, who had a 14.9-Mb deletion at chromosome 3q13.22-13.1 (ref. 57 ) ( Supplementary Fig. 11 ). The EFCAB12 variant was inherited from a heterozygous unaffected mother, whereas the CNV occurred de novo 57 ( Supplementary Fig.11 ). A query of 15,469 control individual exomes at the Institute of Genomic Medicine at Columbia University did not reveal any homozygous or compound heterozygous truncating variants, thus suggesting that biallelic truncating mutations are probably not tolerated in humans. This finding further points toward recessive mutations in EFCAB12 as contributors to the developmental syndrome of this individual. Additionally, we performed clinical annotation of genes known to be implicated in Mendelian forms of CAKUT by querying WES data for an in-house gene list as previously described 58 . We did not find any pathogenic variants in known CAKUT genes for any of the 23 deletion carrier patients. Hence, our WES studies suggest haploinsufficiency as the main pathogenetic mechanism for the CAKUT-associated deletion CNVs.
CAKUT is a common phenotype in the 16p11.2 microdeletion syndrome. We identified nine CAKUT cases and five controls with overlapping 16p11.2 microdeletions (0.32% versus 0.02%; OR 13.7, 95% CI 4.1-52.2; P = 4.39 × 10 −6 ; Fig. 2 , Table 3 and Supplementary  Tables 9 and 10 ), thus implicating CAKUT as an important feature of this syndrome. To better estimate the prevalence of genitourinary malformations in individuals with this GD-CNV, we first analyzed the clinical reports from 186 cases with 16p11.2 microdeletion syndrome in the DECIPHER database (Supplementary Table  14 ). The most prevalent associated conditions were abnormalities of the nervous system (92.5%), abnormalities of the head or neck (26.9%), growth defects (23.7%) and abnormalities of the limbs (14.5%). Abnormalities of the genitourinary system (including KA, hydronephrosis and VUR) were reported in only ten cases (5.4%), but these estimates probably reflect the standard clinical indication for ordering a DNA microarray for diagnosis of a syndromic disease, that is, neurodevelopmental delay and dysmorphic features.
Abnormalities of the skeletal system, which are a hallmark of the 16p11.2 microdeletion syndrome 59, 60 , were reported in only 19 cases (10.2%), because, similarly to individuals with CAKUT, these patients are rarely referred for genetic testing. To obtain a more unbiased estimate of prevalence of genitourinary defects in patients with 16p11.2 microdeletion, we queried the data warehouse of the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia (CHOP). We analyzed the medical records of 42 children with the 16p11.2 microdeletion syndrome (Supplementary databases of genomic variants such as DECIPHER 37, 38 and ISCA 35 and found a known link to CAKUT 5, 23, 26, [39] [40] [41] [42] [43] [44] [45] [46] or case series or reports in which CAKUT was part of the clinical phenotype [47] [48] [49] [50] [51] [52] [53] in 43 out of 45 GD-CNVs. This finding underlines that these GD-CNVs are causally related to CAKUT. Although most GD-CNVs affected unique or few cases ( Supplementary Table 8 ), six loci explained 73 of the 112 (65.2%) subjects who carried a known GD-CNV (Fig. 2) . These common GD loci included chromosome 1q21.1 (seven (6.3%) cases with a GD-CNV; five deletions, two duplications), chromosome 4p16. renal hypoplasia and dysplasia, and obstructive uropathy characterized by hydronephrosis and hydroureter ( Table 4 and Fig. 3a-l ). Microscopic analysis of renal tissue from Tbx6 rv/embryos at stages from E13.5 to E18.5 showed variable severity of kidney anomalies ( Fig. 3d -l). Severe phenotypes included unilateral or bilateral renal agenesis, rudimentary kidneys and undeveloped renal parenchyma embedded in the paraspinal musculature ( Fig. 3f ,i,l). Milder phenotypes included unilateral and bilateral renal hypoplasia with hydroureter, tubule dilation and hydronephrosis ( Fig. 3e ,h,k). These data strongly implicate TBX6 as a major driver of CAKUT phenotypes. Comparative analysis was performed on wild-type and Tbx6 rv/embryos at E11.5 after staining with E-cadherin (Cdh1), an epithelial marker, which labels the common nephric duct and the ureteric bud, which gives rise to the collecting duct system, and Pax2, which prevalently labels mesenchymal progenitors that produce nephrons [72] [73] [74] . This analysis revealed that the events leading to CAKUT (renal parenchyma abnormalities and obstruction) are present at early stages during development ( Fig. 3m,n) . In wild-type E11.5 embryos, the ureteric bud had invaded the metanephric blastema and had undergone a round of branching ( Fig. 3n ). In the Tbx6 rv/mutant ( Fig. 3n ), the ureteric bud had not fully invaded the metanephric blastema and had not branched, a defect predicted to lead to KA. Additional Cdh1-positive cells in Fig. 3n might represent persistent mesonephros or ectopic ureteric buds; in that possibility, ectopic buds would explain the duplication of kidney and ureter phenotype, as observed in Fig. 4 . Because more subtle CAKUT phenotypes such as OU or DCS may require a minimum glomerular filtration rate or might be masked in more severe models, we examined a milder model that might be closer to the genetic architecture of humans with 16p11.2 microdeletion syndrome. We therefore analyzed embryos homozygous for the Tbx6 hypomorphic allele (Tbx6 rv/rv ). We generated 25 homozygous Tbx6 rv/rv animals at E15.5 (n = 10), E18.5 (n = 10) and postnatal day (P) 0 (n = 5) and observed incomplete penetrance and variable expressivity of multiple phenotypes that are typical of human CAKUT, including mild unilateral or bilateral hypoplasia with asymmetric kidneys, bifid ureter or DCS, and OU with profound hydronephrosis ( Table 4 and Fig. 4 ). This pleiotropy of CAKUT phenotypes, ranging from renal parenchyma defects (KA) to hydronephrosis (OU) or duplication of ureters (DCS), is highly reminiscent of the pleiotropic manifestations of the 16p11.2 microdeletion in humans, thus suggesting that TBX6 gene dosage is a major determinant of the pathogenesis of CAKUT and the observed variable expressivity of phenotypes in this syndrome.
Discussion
CAKUT has a profound effect on child health and alone accounts for about 50% of kidney failure requiring dialysis and transplantation Table 15 ). Neurodevelopmental defects and brain anomalies and spine defects were the most prevalent conditions, recorded in 22 (52.4%) and 6 (14.2%) cases, respectively. Imaging studies and clinical data assessing the kidney and urinary tract were available for 15 out of 42 cases, and genitourinary anomalies were present in 9 of 15 cases (40.0%), thus highlighting that CAKUT, similarly to scoliosis, is a common feature in this syndrome and is characterized by incomplete penetrance. In agreement with our observation of a high pleiotropic effect for the 16p11.2 microdeletion, the phenotype was also variable in this cohort: two patients with OU, two with VUR, one with PUV and one with LUTM. These data implicate CAKUT as a major feature of the chromosome 16p11.2 microdeletion syndrome and provide an opportunity to identify novel key regulators of kidney and urinary tract development.
TBX6 is a driver of CAKUT in the 16p11.2 microdeletion syndrome. We have recently demonstrated that the combinatorial use of genomic analyses with functional modeling in vertebrates can lead to the identification of key drivers of CAKUT phenotypes from microdeletion syndromes 23 . Analysis of breakpoints in nine CAKUT cases with typical or atypical 16p11.2 microdeletions identified a ~175-kb minimal region of overlap predicted to harbor the genetic driver(s) for CAKUT ( Supplementary Fig. 12 ). Among the 19 genes included in the minimal region of overlap, TBX6 appeared as a strong candidate: it is included in the list of essential genes from the International Mouse Phenotyping Consortium 61 ; it is depleted from LOF mutations in subjects from the ExAC database (aggregate prevalence of LOF < 0.001); it has a role in paraxial and intermediate mesoderm development 62, 63 ; and its inactivation in humans and rodents leads to spine defects, including congenital scoliosis and spondylocostal dysostosis 59, 62, [64] [65] [66] . The connection of TBX6 mutations with vertebral anomalies is of particular interest because of the historically well-known clinical association between congenital scoliosis and CAKUT [67] [68] [69] .
To provide a functional link between the inactivation of TBX6 and CAKUT, we generated an allelic series by cross-breeding mice with two different alleles, a Tbx6-null allele (Tbx6 tm2PA ) 70 and a Tbx6 hypomorphic allele, the spontaneous mutant Tbx6 rv (hereafter referred to as Tbx6and Tbx6 rv , respectively), which has been studied for vertebral development and spine defects 71 . Because the homozygous null mutation is lethal at embryonic day (E) 9.5, thus precluding analysis of the developing urinary tract, we first studied compound heterozygous embryos (Tbx6 rv/-), which retain sufficient residual expression of Tbx6 for survival past E9.5. We studied 19 Tbx6 rv/embryos at E17.5-E18.5 and observed full penetrance of CAKUT with variable expressivity of phenotypes characterized by unilateral or bilateral renal agenesis, unilateral or bilateral Based on gross morphology only. We analyzed four Tbx6 +/and six Tbx6 +/rv E18.5 embryos according to gross morphology, thus hampering ability to assess milder phenotypes and incomplete penetrance in these embryos.
kidney disease and to mitigate the associated neurocognitive and cardiac disease. In this respect, it is relevant to address two features of CAKUT: incomplete penetrance and variable expressivity of disease. Whereas prediction of a targeted treatment that prevents or reverses the disease is still limited by current knowledge, understanding the intrinsic interindividual mechanisms of in children 1, 3, [75] [76] [77] [78] . Moreover, CAKUT is often accompanied by extrarenal comorbidities, such as neurodevelopmental and cardiovascular diseases, thus contributing further to the disease burden in affected children 5, 26, 27, 79 . Understanding the genetic architecture of CAKUT has important implications for the development of therapeutic tools that aim to slow the progression of , which are indicative of hydronephrosis and hydroureter, respectively. In e, the kidney parenchyma also appears severely hypoplastic. The arrowhead in F points to the rudimentary kidney, which is embedded in paraspinal musculature. Few dilated tubule and microcysts are present. g-i, H&E stained kidney from an E15.5 wild type embryo (g) and E15.5 Tbx6 rv/mutant embryos (h,i). The mutants show moderate to severe hypoplasia with reduction of nephrogenic zone (nz) (h); the arrowhead indicated severely underdeveloped kidney tissue with tubule dilation and microcysts (i). j-l, H&E histological analysis of kidneys from E13.5 wild type embryos (j) and Tbx6 rv/mutants (k,l). The arrowheads point to the rudimentary kidneys that are embedded in the body wall. m,n, Immunostaining of E11.5 wild type and Tbx6 rv/mutant embryos stained with Pax2 (red) and Cdh1 (green) showing the ureteric bud (ub) nephron progenitors (np) and nephric duct (nd). In the wild type embryo, the ureteric bud has invaded the metanephric mesenchyme and branched, whereas in the mutant, the ureteric bud has not fully invaded the metanephric mesenchyme.
16p11.2, in which patients with deletions show macrocephaly, and patients with duplications are microcephalic 90, 91 . Larger human cohorts and experimental data will be required to investigate this hypothesis. A closer look at common GD loci assigns specificity to CAKUT subcategories, such as deletions, but not duplications, at 4p (Wolf-Hirschhorn syndrome) 92 , 17q12 (renal cysts and diabetes syndrome) 40 and 22q11.2 (DiGeorge syndrome) 93 , which were nearly exclusively identified in cases with upper urinary tract malformations (mainly KA). On the other end, microdeletions at 16p11.2 were observed across the entire phenotypic spectrum of CAKUT, thus underlining the highly pleiotropic effect of this genomic region on human kidney and urinary tract development.
The finding that pleiotropic urogenital defects are an important feature of this syndrome was replicated in two independent series from DECIPHER and CHOP. We previously reported on the potential of large-scale genetic studies coupled with functional modeling in vertebrates in the identification of genetic drivers for kidney phenotypes of microdeletion syndromes 23 . Here, we focused on the 16p11.2 microdeletion syndrome, because its pleiotropic effect and incomplete penetrance provide an ideal scenario to identify genetic factors that might aid in devising therapeutic intervention. Deletion mapping and prioritization analyses pointed to TBX6 as the main genetic driver for CAKUT in cases with this syndrome. Tbx6 mouse allelic series showed that compound heterozygous embryos for a null (Tbx6 tm2Pa ) and a hypomorphic (Tbx6 rv ) allele displayed fully penetrant CAKUT with variable expressivity of phenotypes, from bilateral renal agenesis to hypodysplasia and obstructive uropathy. Analysis of E11.5 embryonic tissue stained for renal progenitors and epithelial markers suggested that the initiating events for the CAKUT phenotypes are likely to occur very early in development in these mice. These data are in line with results from recent fate-mapping studies showing that Tbx6 is expressed in renal progenitor cells before commitment to ureteric bud or metanephric mesenchyme lineages 94 . When we analyzed embryos and mice with milder Tbx6 inactivation (Tbx6 rv/rv ) as a closer model to the human 16p11.2 microdeletion, we observed incomplete penetrance of multiple kidney and urinary tract malformations. Interestingly, similarly to the observations in our 16p11.2 microdeletion cases, we observed that the mutant mice showed phenotypes across the phenotypic spectrum of CAKUT, including KA, OU and DCS. Overall, our mouse data at least partly suggest that the variable expressivity and incomplete penetrance of CAKUT in cases with the 16p11.2 microdeletion are attributable to a fine regulation of TBX6 gene expression during organogenesis.
In summary, with this study on children and young adults with kidney and urinary tract malformations, we provide substantial insight into the genomic landscape of human CAKUT. We identify several susceptibility genetic loci and genes, and we highlight TBX6 as a main genetic driver for CAKUT in subjects with the chromosome 16p11.2 microdeletion syndrome, with notable implications for understanding, and potentially modifying, disease penetrance. compensation or amplification of disease are critical for devising treatments that might slow or halt the progression of kidney disease and associated extrarenal malformations.
URLs
The study of CNVs has provided enormous insight into the genetic architecture of many developmental traits [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] . We conducted a large study on rare CNVs in nearly 3,000 CAKUT cases and over 21,000 controls. By studying the burden of rare CNVs, we identified that KA, OU and VUR are particularly enriched for large and rare structural variants that affect coding regions of the genome. When examining known GD-CNVs, we found particular enrichment in CAKUT cases with KA, OU, DCS and PUV compared with controls. Overall, we identified 45 distinct GDs at 37 independent genomic loci in 4% of the CAKUT cases, thus indicating substantial genetic heterogeneity. We identified novel GD-CNVs in an additional ~2% of CAKUT cases, providing multiple novel susceptibility loci to kidney disease. With respect to mechanism, WES in cases with deletions was consistent with haploinsufficiency as the most frequent pathogenic mechanism in individuals affected by GD-associated deletions. Moreover, increased burden of second-site CNVs was associated with KA and increased prevalence of extrarenal malformations. These data indicate a role for background genomic burden in variable penetrance and expressivity of disease. CNVs at six of the known 37 loci accounted for ~65% of the cases with a known GD, thus identifying major susceptibility CNVs for CAKUT. At these six loci, deletions were associated with KA, whereas duplications were enriched in cases with ureteric and lower tract defects, such as DCS and PUV. This preliminary observation gives rise to the hypothesis that CAKUT subcategories such as ureteric and lower urinary tract defects (DCS, PUV) may represent, at a molecular level, mirror traits of conditions affecting the upper urinary tract (KA, OU). This 'mirroring phenomenon' has been recognized in autism spectrum disorder caused by structural variation at the 
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Whole-exome sequencing. Whole-exome sequencing was performed on 23 patients with CAKUT with 14 distinct known or novel GD-CNVs at the New York Genome Center (NYGC). Briefly, for each capture experiment, 1 μ g of genomic DNA was fragmented, linkers were ligated to the ends, and a library was prepared. Next, genomic DNA was annealed to Agilent V4 capture probes, and bound genomic DNA was eluted and subjected to next-generation sequencing performed on an Illumina HiSeq 2500 machine. Sequence reads were converted to FASTQ format and mapped to the reference genome. We used uniform procedures for variant calling to prevent technical bias. Samples were processed with a consistent alignment and variant-calling pipeline consisting of primary alignment with bwa-0.5.10, duplicate removal with Picard tools, index realignment and variant calling with GATK 3.6 and variant annotation with snpEff-3.3, AnnoVar (see URLs) and SeattleSeq (see URLs), with Ensembl-GRCh37.73 annotations. After variant calling, the resultant calls and their underlying quality statistics were then stored in a database of variants (AnnoDB) that is used by Analysis Tool for Annotated Variants (ATAV) analyses (see URLs). Next, we queried ATAV for the individual deleted regions of all 23 CAKUT cases and annotated all hemizygous variants (minimal coverage > 8× , minimal genotype quality score > 30) with a minor-allele frequency of < 1% (autosomal-recessive model) in the ExAC database and in 3,653 ancestrally matched available in-house controls and with a combined annotation-dependent depletion (CADD) score >20 (that is, strongly predicted to be deleterious). We retained one homozygous variant in one individual CAKUT case: a homozygous truncating mutation in EFCAB12 found in a case with a 14.9-Mb deletion at chromosome 3q13.22-13. The variant was confirmed by Sanger sequencing according to standard protocols. Finally, we queried the ExAC database as well as the data warehouse of the Columbia Institute of Genomic Medicine (IGM), which contains whole-exome data for 15,469 control individuals recruited for other reasons than chronic kidney disease. We did not find any homozygous or compound heterozygous truncating variants in EFCAB12. We performed clinical annotation of genes known to be implicated in Mendelian forms of CAKUT by querying WES data for an in-house gene list, as previously described 58 . We did not find any pathogenic variants in known CAKUT genes for all deletion-carrier patients Generation and analysis of Tbx6 mutant mice and embryos. The null-allele nullexpression reporter allele, Tbx6 tm2Pa , which has deletion of exon 2 and part of exon 3 and has an H2B-EYFP fusion gene inserted in frame into exon 1 (ref. 70 ), was maintained on a mixed genetic background of 129 and ICR (Taconic). B6L-Tbx6 rv /J mice (JAX) were mated with C57BL/6Tac mice (Taconic) and maintained in a small, closed colony. Embryos were collected from timed matings of mice heterozygous for either allele, and noon on the day of the plug was considered E0.5. Embryos were genotyped via PCR with the following primers pairs for Tbx6 tm2Pa (i) 5′ -GTACCATCCACGAGAGTTGTAC-3′ ; (ii) 5′ -GGGAAGAATGAGGATCCAGG-3′ , to obtain a 220-bp wild-type allele fragment; (iii) 5′ -ATTGCACGCAGGTTCTCCGG-3′ ; and (iv) 5′ -GTCACGACGAGATCCTCGCC-3′ , to obtain a 550-bp mutant allele fragment. For Tbx6 rv : (i) 5′ -CTCGCAGCTTCACTAGTCC-3′ and (ii) 5′ -GTGTCTGGCGTATCAGCTCA-3′ , to obtain a 322-bp wild-type allele fragment and 504-bp mutant allele fragment.
We analyzed different allele combinations for the Tbx6-null (Tbx6 tm2Pa ) and hypomorphic (Tbx6 rv ) alleles. For H&E staining: embryos were fixed overnight in 4% paraformaldehyde and dehydrated through a graded ethanol series (25-50-75-100%), then washed with xylene. The embryos were incubated in two changes of paraffin wax at 55 °C under vacuum. The embryos were then embedded in paraffin wax and sectioned at 10 µ m. Sections were dewaxed in xylene, rehydrated through ethanol, stained with Harris H&E-Y and dehydrated before mounting in Cytoseal. For immunostaining, embryos were fixed in 4% araformaldehyde. Tissues were dehydrated into 100% methanol postfixation. For sectioning, tissues were embedded in paraffin or frozen in OCT and sectioned at various thicknesses (5-20 µ m). Paraffin sections were deparaffinized with Histoclear and rehydrated via an ethanol series. Cryosections were prepared for immunolabeling by removal of OCT by washing in PBS. Antibodies were as follows: Cdh1, goat, R&D AF741, 1:400 dilution; Pax2, rabbit, Zymed 716000, 1:70.
Statistical analysis. All burden metrics calculations, statistical tests and plots were performed or generated in R v3.1 software (see URLs) and its dplyr (see URLs), survival (see URLs) and ggplot2 (ref. 99 ) packages, and the Python v2.7 language (see URLs) and its packages pandas 100 and lifelines (see URLs). Unadjusted P values were reported for all tests. Summary statistics (mean, standard deviation, median and interquartile range) were calculated for CNV metrics such as size and total span, and the nonparametric Wilcoxon test was used for comparison between cases and controls. Proportions were compared with a two-sided Fisher's exact test. Kaplan-Meier survival curves were calculated to represent the largest CNV per genome, and a nonparametric log-rank test was used to compare the survival distributions between cases and controls. Logistic regression was used to test whether the number of genes intersected by large and rare CNVs detected (quantitative predictor) was associated with the case-control status (outcome). The reciprocal cumulative distributions of the number of intersected genes in cases versus controls were plotted.
Methods
Ethical statement. All aspects of the study involving human research participants adhered to the principles of the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Boards (IRB) of Columbia University Medical Center and each participating recruitment site. Signed written informed consent from the participant and/or their parents or guardians was obtained according to the protocols of the local IRBs.
All animal experiments followed protocols approved by the Institutional Animal Care and Use Committee at Columbia University.
Study subjects. CAKUT cases consisted of 2,824 affected, unrelated individuals with different subphenotypes across the entire CAKUT spectrum. Individuals were recruited in the United States, Europe and Brazil (overview of recruitment sites in Supplementary Fig. 1 ). The baseline characteristics of the study cohort are shown in Supplementary Table 1 . One in every four cases presented with more than one CAKUT phenotype (that is, complex CAKUT), whereas a substantial proportion of patients had extrarenal manifestations, such as neurocognitive defects, congenital heart disease or dysmorphic features. A positive family history for renal disease was identified in 15% of the cases. Cases included CAKUT patients from the CKiD 27 and KIMONO 28 studies; genotyping results of 823 (29%) subjects had been partially reported in previous publications 23, [26] [27] [28] . The control population consisted of 21,498 individuals recruited as part of genome-wide genotyping studies of complex traits that are not associated with nephropathy or developmental defects (Supplementary Table 2 ).
CNV discovery and annotation. Genomic DNA was obtained from peripheral blood samples or, in the case of CKiD participants, lymphoblastoid cell lines derived from peripheral blood samples. Genome-wide genotyping was performed in all cases and controls with HumanHap550 or higher-density Illumina (San Diego, CA, USA) or Affymetrix SNP6.0 (Santa Clara, CA, USA) microarrays (Supplementary Table 2 ). Raw data processing and subsequent analyses were performed in the same fashion for both cases and controls to avoid bias.
Raw data were first processed with Affymetrix Power Tools and the PennCNV-Affy protocol or with Illumina GenomeStudio v2011 to obtain probe-level logRratio and b allele frequency values. PennCNV software 95 was used to determine CNV calls. PennCNV and PLINK software 96 were used for quality control. Principal component analysis (PCA) was conducted by using smartPCA 97 based on SNP genotypes derived from the same genotyping arrays. CNV calling and all analyses were performed on hg18 coordinates; CNVs were then mapped to hg19 in UCSC liftover software (see URLs). Only high-quality CNVs with confidence scores ≥ 30 were included in the analyses based on independent experimental validation from our prior CNV study on KA 26 .
CNVs in subjects were compared with those in controls and known CNV coordinates and were annotated with RefGene (see URLs) and curated sets of genes with custom Perl code 98 . Known CNVs were based on the DECIPHER 37,38 and the International Standards for Cytogenomic Arrays (ISCA) databases 35 and the literature ( Supplementary Table 7 ). Curated sets of genes included those known to be associated with kidney disease and/or development from the OMIM and MGI databases and the literature. Two CNVs were considered to be identical when they had the same copy number value and had a reciprocal overlap ≥ 70%. All reported CNVs were visually inspected in Illumina Genome Viewer 1.9.0 or Affymetrix ChAS to exclude potential artifacts. CNV classification. CNVs were classified as known genomic disorders (GD-CNV) or likely pathogenic CNVs ('novel GD-CNV'). A CNV was defined as a known GD-CNV when it overlapped at least 70% of a known syndromic CNV. The criteria to define a likely pathogenic CNV were adapted from prior recommendations for interpretation of microarray data [26] [27] [28] 35, 36 . A CNV was classified as likely pathogenic if it (i) intersected at least one exon, (ii) was at least 100 kb in size, (iii) had a frequency in controls of at most 0.02%, (iv) did not overlap (< 70%) with a benign or likely benign CNV in the ISCA database, and fulfilled at least one of the following additional criteria: (i) had ≥ 70% overlap with a reported pathogenic or likely pathogenic CNV in the ISCA database, (ii) intersected a causative autosomaldominant gene for CAKUT in humans or mice, and/or (iii) was the reciprocal of a known GD-CNV (coordinates with ≥ 70% overlap). Known GD-CNVs and likely pathogenic CNVs together were termed 'diagnostic CNVs' . CNVs that did not meet the criteria for diagnostic CNVs were defined as variants of unknown significance if they were at least 100 kb in size and had a frequency of at most 0.1% in controls, including homo-and hemizygous deletions of loci underlying a recessive disorder for human disease with a renal phenotype.
CNV burden analysis. We restricted burden analyses to autosomal CNVs ≥ 100 kb in cases and controls, with a frequency ≤ 1% in the whole control dataset and in any one control cohort comprising it. CNVs were further filtered at a frequency ≤ 0.1% in control population subgroups on the basis of PCA, to avoid including CNVs that might be relatively common within ancestry groups represented in controls. Before the CNV burden was determined, seven cases (five KA, five vesicoureteral reflux and one lower urinary tract malformations) and eight controls were removed because they were unmatched outliers in PCA, thus yielding a dataset of 2,817 cases and 21,490 controls for burden analyses. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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